Browsing Tag
advanced melanoma
2 posts
Replimune Group (NASDAQ: REPL) plans layoffs after FDA rejects Tudriqev again, forcing a biotech reset
Replimune plans layoffs after the FDA rejected Tudriqev again. Read what the setback means for REPL stock, cash runway, strategy, and rivals.
Advanced melanoma immunotherapy enters a new phase as Scancell secures Phase 3 clearance
Scancell Holdings Plc, iSCIB1+, advanced melanoma, melanoma immunotherapy, FDA Phase 3 clearance, cancer vaccines, ImmunoBody platform